EUCTR2005-003772-37-IT进行中（未招募）不适用
A randomized, open label, multicentre, phase 3 trial to assess the safety of Tobramycin Inhalation Powder compared to TOBI in cystic fibrosis subjects - TIP003
CHIRON CORPORATION LIMITED0 个研究点目标入组 500 人开始时间: 2006年6月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Confirmed diagnosis of cystic fibrosis by sweat test with 60 mEq/L or higher chlorine content, by documented quantitative pilocarpine iontophoresis QPIT or by homozygosis for 61508;F508 genetic mutation or by heterozygosis for two well-characterized mutations and two clinical findings coherent with CF diagnosis. Subjects of both sexes aged 61619; 6 years at moment of screening. FEV1 at screening must be 61619; 25 and 61603; 75 compared with value normally predicted for age, sex and height, based on Knudson criteria. P. aeruginosa must be present in culture grown on sputum/pharyngeal swab or bronchoalveolar lavage BAL during the six months prior to screening and in culture grown on sputum/pharyngeal swab at screening visit. Subjects capable of adhering to protocol requirements. Clinically stable in researcher s opinion. Use of an effective contraceptive method for women potentially able to bear children. Written informed consent, HIPAA authorization where applicable and agreement as appropriate before any procedure connected with trial is carried out.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of culture grown on sputum/pharyngeal swab or BAL that showed Burkholderia cepacia B cepacia within the 2 years prior to screening and/or culture grown on sputum that shows B cepacia at screening. Haemoptysis greater than 60 cc at any moment during the 30 days prior administration of the drug under investigation. Known local or systemic hypersensitivity to aminoglycosides or antibiotics by inhalation. Serum creatinine 2 mg/dl or higher, BUN 40 mg/dl or higher, or altered urine test defined as proteinuria 2 or greater. Pregnant women positive pregnancy test , breastfeeding women, and women planning a pregnancy during the trial period. History of hypoakusis or chronic tinnitus considered clinically significant by the researcher. Use of systemic or inhaled anti-pseudomonas antibiotics during the 28 days prior to administration of the drug under investigation. Use of ansa diuretics during the 7 days prior to administration of the drug under investigation. Use of any therapy under investigation during the 28 days prior to administration of the drug under investigation. Chronic therapy with macrolides started during the 28 days prior to administration of the drug under investigation subjects may take macrolide therapy at the moment of enrolling in TIP003, but have to have started the treatment more than 28 days before administration of the drug under investigation . Treatment with dornase alfa started during the 28 days prior to administration of the drug under investigation subjects may take treatment with dornase alfa at the moment of enrolling in TIP003, but have to have started the treatment more than 28 days before administration of the drug under investigation . Treatment with inhaled steroids or increase in dosage during the 28 days prior to administration of the drug under investigation subjects may take inhaled steroids at the moment of enrolling in TIP003, but have to have started the treatment more than 28 days before administration of the drug under investigation .
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis SubjectsPulmonary pseudomonas aeruginosa infections in patients with cystic fibrosisClassification code 10011762EUCTR2005-003772-37-DEovartis Pharma Services AG500
进行中（未招募）
1 期
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects - TIP003EUCTR2005-003772-37-IEovartis Pharma Services AG500
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects - TIP003EUCTR2005-003772-37-GBovartis Pharma Services AG500
进行中（未招募）
1 期
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects - ASPIRE IIEUCTR2005-003772-37-GRovartis Pharma Services AG
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects - TIP003Pulmonary pseudomonas aeruginosa infections in patients with cystic fibrosisClassification code 10011762EUCTR2005-003772-37-HUovartis Pharma Services AG500